Localization of the Domains of the Haemophilus ducreyi Trimeric Autotransporter DsrA Involved in Serum Resistance and Binding to the Extracellular Matrix Proteins Fibronectin and Vitronectin by Leduc, I. et al.
INFECTION AND IMMUNITY, Feb. 2009, p. 657–666 Vol. 77, No. 2
0019-9567/09/$08.000 doi:10.1128/IAI.00819-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Localization of the Domains of the Haemophilus ducreyi Trimeric
Autotransporter DsrA Involved in Serum Resistance and
Binding to the Extracellular Matrix Proteins
Fibronectin and Vitronectin
Isabelle Leduc, Bonnie Olsen,† and Christopher Elkins*
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
Received 2 July 2008/Returned for modification 13 August 2008/Accepted 4 November 2008
Resisting the bactericidal activity of naturally occurring antibodies and complement of normal human serum is
an important element in the evasion of innate immunity by bacteria. In the gram-negative mucosal pathogen
Haemophilus ducreyi, serum resistance is mediated primarily by the trimeric autotransporter DsrA. DsrA also
functions as an adhesin for the extracellular matrix proteins fibronectin and vitronectin and mediates attachment
of H. ducreyi to keratinocytes. We sought to determine the domain(s) of the 236-residue DsrA protein required for serum
resistance and extracellular matrix protein binding. A 140-amino-acid truncated protein containing only the C-terminal
portion of the passenger domain and the entire translocator domain of DsrA exhibited binding to fibronectin and
vitronectin and conferred serum resistance to an H. ducreyi serum-sensitive strain. A shorter DsrA construct consisting
of only 128 amino acids was unable to bind to extracellular matrix proteins but was serum resistant. We concluded that
neither fibronectin binding nor vitronectin binding is required for high-level serum resistance in H. ducreyi.
Haemophilus ducreyi is the etiologic agent of the sexually trans-
mitted genital ulcer disease chancroid (23, 31, 35). H. ducreyi is
highly resistant to the bactericidal activity of human serum com-
plement (serum resistance) (13, 21). Several outer membrane
proteins of H. ducreyi, including DsrA (Ducreyi serum resistance
A) (13), DltA (Ducreyi lectin A) (21), and MOMP (Major Outer
Membrane Protein) (18), are involved in serum resistance. The
mechanism(s) of serum resistance involving DltA and MOMP
has not been elucidated yet; however, DsrA mediates protection
from the activity of complement by preventing deposition of se-
rum bactericidal immunoglobulin M (IgM) at the surface of H.
ducreyi (1). DsrA is also necessary and sufficient to confer binding
to the extracellular matrix (ECM) proteins vitronectin (VN) (9)
and fibronectin (FN) (22) and to HaCat keratinocytes (9). An H.
ducreyi isogenic dsrA mutant is not able to cause pustules in the
human model of chancroid, establishing that DsrA is a virulence
factor (8). A second class of H. ducreyi strains, termed class II
strains, express a DsrA protein that is only 47.8% identical to the
DsrA protein expressed by class I strains; however, the last 86
residues of the DsrA protein expressed by class II strains are
88.5% identical to the same region of the DsrA protein expressed
by class I H. ducreyi strains (38). Despite these primary sequence
differences, DsrA proteins expressed by both classes of H. ducreyi
strains confer serum resistance, as well as FN and VN binding
(22).
DsrA is part of the trimeric autotransporter adhesin (TAA)
family of proteins, a subset of a large family of bacterial pro-
teins termed autotransporters (11, 17). Autotransporter pro-
teins are organized in three domains: an N-terminal signal
peptide, a passenger or effector domain, and a C-terminal
translocator or  domain (11). The passenger domain includes
the head, neck, and stalk, while the coiled-coil and membrane
anchor comprise the translocator domain. Autotransporter
proteins are exported through the inner membrane into the
periplasm by a Sec-dependent process (12). Once the proteins
are in the periplasm, it is hypothesized that the translocator
domain of autotransporters inserts into the outer membrane
and exports the passenger domain to the bacterial cell surface,
although it is unclear how this is accomplished (11, 12). In
TAAs, the translocator domain is formed by the interaction
between the C-terminal domains of three monomers, and each
monomer contributes 4 strands to the 12-strand  barrel of the
TAA homotrimer. The C-terminal translocator domain of
TAAs is highly conserved and is the defining element of the
family (24).
The mechanism by which DsrA prevents binding of bacteri-
cidal serum IgM at the surface of H. ducreyi is not understood.
The DsrA trimer is abundantly expressed at the surface of H.
ducreyi, and it is possible that binding of large proteins, such as
FN and VN, by DsrA shields epitopes of surface-exposed H.
ducreyi proteins. VN binding by DsrA may also be involved in
serum resistance since VN is an inhibitor of the complement
cascade. In order to determine the functional domains of
DsrA, we constructed mutants with in-frame deletions of the
passenger domain of dsrA and characterized their serum resis-
tance and FN and VN binding phenotypes.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Bacterial strains and plasmids used in
this study are listed in Table 1. H. ducreyi strains were routinely maintained by
minimal subculture on chocolate agar (CA) plates containing 1 GGC (0.1%
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glucose, 0.01% glutamine, 0.026% cysteine) (34) and 5% FetalPlex (Gemini,
California) and incubated at 34.5°C in the presence of 5% CO2. Haemophilus
influenzae strains were maintained on CA plates containing 1% IsoVitaleX
(Becton Dickinson, New Jersey). For the VN and FN binding assays (see below),
H. ducreyi strains were grown on heme agar consisting of gonococcal medium
containing 1 GGC and 50 g/ml hemin. Streptomycin (100 g/ml) was added
to media when it was appropriate.
Protein sequences used for alignment. The following sequences were used for
the sequence alignment shown in Fig. 1: gi 7188573 (accession no. AAF37807)
(DsrA class I [DsrAI]) (13), gi 51873258 (accession no. AAU12589) (DsrA class
II [DsrAII]) (38), gi 32470319 (accession no. NP_863557) (YadA with 422 amino
acids in the immature protein sequence [YadA1]), gi 401465 (accession no.
P31489) (YadA with 455 amino acids in the immature protein sequence
[YadA2]) (19), and gi 58004002 (accession no. AAW62383) (UspA2 with 650
amino acids in the immature protein sequence [UspA2]) (5). CLUSTALW was
used to construct the alignment (http://workbench.sdsc.edu).
Construction of in-frame dsrA deletion mutants. In-frame dsrA deletion mu-
tations were expressed in H. ducreyi isogenic dsrA mutant strain FX517
(35000HP dsrA) (13). The dsrA gene in strain FX517 is insertionally inactivated
with a chloramphenicol acetyl transferase cassette. Strain FX517 has been ex-
tensively characterized at the DNA and protein levels and does not express
full-length or breakdown products of the DsrA protein (8).
Using a reverse PCR strategy, a plasmid containing an in-frame deletion of the
complete passenger (variable) domain of dsrA (with nucleotides 73 to 510 of the
dsrA open reading frame [ORF] removed) was constructed. This plasmid re-
tained the coiled-coil and membrane anchor domains (termed the translocator
region) of DsrA, which previously was shown to be necessary for transport of
YadA to the bacterial surface and oligomerization of YadA (29). Primers
DsrA611s and DsrA121s were used with pUNCH1260 as the template to PCR
amplify the signal sequence and translocator domains of the dsrA gene. The
following amplification parameters were used: a single denaturation step of 5
min at 96°C, followed by 30 cycles consisting of 1 min of denaturation at 96°C,
annealing at 52°C for 1 min, and extension at 72°C for 4 min and then a final
10-min cycle at 72°C. The Deep Vent DNA polymerase (New England Biolabs,
Massachusetts), with its appropriate buffer, was used for this amplification reac-
tion. A PCR product of the expected size (4,091 bp) was digested with XmaI,
ligated, and electroporated in H. ducreyi strain FX517. Colonies were selected on
streptomycin-containing CA plates, subcultured, and examined for expression of
a protein that was the appropriate size (9.4 kDa) (Fig. 1) using Western blotting
with an antibody to full-length recombinant DsrAI (rFL-DsrAI), anti-rFL-DsrAI
(38). One clone that was the appropriate size was chosen and designated
pUNCH1424 after confirmation of its DNA sequence (UNC-CH Sequencing
Facility).
Reverse PCR was also used to construct dsrA deletion mutants pUNCH1425
and pUNCH1426. In this case, primer DsrA121s was used with forward primers
DsrA3776F and DsrA3737F to construct pUNCH1425 and pUNCH1426, re-
spectively. The PCR conditions were the same as those described above, except
that annealing was carried out at 43°C and the extension step was 5 min long. The
resulting PCR products were digested with XmaI and electroporated in FX517.
Clones were screened and sequenced as described above for pUNCH1424.
To construct pUNCH1427, pUNCH1428, pUNCH1429, pUNCH1430, and
pUNCH1431, various lengths of the passenger (variable) domain of the dsrA
ORF (termed the cassette) were amplified from pUNCH1260 and inserted into
pUNCH1424. To accomplish this, XmaI sites were incorporated into the primers
so that PCR products could be ligated to pUNCH1424, which has an XmaI
restriction site between the signal sequence and the translocator domain of dsrA.
Selected primers (Table 2) and pUNCH1260 (as the DNA template) were used
under the following conditions: a single denaturation step at 95°C for 5 min,
followed by 35 cycles consisting of 1 min of denaturation at 95°C, 1 min of
annealing at 60°C, and 30 s of extension at 72°C and then a single extension step
at 72°C for 4 min. Primers DsrAxG and DsrAxE were used to amplify a cassette
to construct pUNCH1427, primers DsrAxF and DsrAxE were used to amplify a
cassette to construct pUNCH1428, primers DsrAxD and DsrAxE were used to
amplify a cassette to construct pUNCH1429, primers DsrAxC and DsrAxE were
used to amplify a cassette to construct pUNCH1430, and primers DsrAxB and
DsrAxE were used to amplify a cassette to construct pUNCH1431. The resulting
PCR products were digested with XmaI and ligated to XmaI- and alkaline
phosphatase-treated pUNCH1424 prior to electroporation in strain FX517.
Clones were screened and sequenced as described above for pUNCH1424.
Preparation of lipooligosaccharides (LOS). A bacterial suspension (approxi-
mately 4  108 CFU suspended in 200 l Laemmli sample buffer) was incubated
at 56°C for 1 h with proteinase K (50 g/ml). The preparation was boiled for 1
min and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and silver staining (36).
Preparation of OMPs. The outer membrane proteins (OMPs) were prepared
as previously described using bacteria grown in gonococcal medium broth (GCB)
containing 5% FetalPlex, 1 GGC, and streptomycin (21). The OMPs were
suspended in 10 mM HEPES, and the protein contents were determined using a
bicinchoninic acid protein determination kit (Pierce, Illinois).
Whole-cell binding assay. A bacterial suspension (approximately 8  107 CFU
from a 13- to 16-h-old culture grown on CA plates) was incubated for 1.5 h at
room temperature with 50 l of a polyclonal antiserum to the variable N-
terminal domain of DsrA (anti-rNt-DsrAI) (Fig. 2B) (1:200 dilution in 0.25%
Tween 20 in GCB) in a MultiscreenHTS-HV plate (Millipore, Massachusetts).
Prior to the experiment, the serum was adsorbed twice with FX517/pLSSK (50 l
of packed cells) for 30 min at room temperature to remove non-anti-DsrA
antibodies. The wells were subsequently washed four times with 200 l of wash
buffer (0.1% Tween 20 in GCB). An anti-rabbit horseradish peroxidase-conju-
gated secondary antibody (Sigma-Aldrich, Missouri), adsorbed twice with
35000HP, was incubated (1:2,000 dilution in 0.25% Tween 20 in GCB) for 1 h at
room temperature. The wells were washed with wash buffer, and 100 l of
substrate (catalog no. RPN2106; GE Healthcare, United Kingdom) was added to
each well. The plate was read using the luminescence setting and a Wallac 1420
Workstation (Victor2) multilabel plate reader (Perkin-Elmer, Massachusetts).
Each strain was tested in triplicate in each experiment, and each experiment was
conducted at least three times.
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype and/or phenotype Proteinexpressed Reference(s)
H. ducreyi strains
35000HP Wild-type, human-passaged variant of strain 35000 DsrAI 3, 16
FX517 35000HPdsrA::CATa None 13
Plasmids
pLSSK H. ducreyi shuttle vector; Smr None 39
pUNCH1260 Complete dsrA ORF in pLSSK (774 bp; 257 amino acids) DsrAI 13
pUNCH1424 Base pairs 73 to 510 deleted in dsrA (corresponding to amino acids 25 to 170)b DsrAI25-170 This study
pUNCH1425 Base pairs 73 to 474 deleted in dsrA (corresponding to amino acids 25 to 158) DsrAI25-158 This study
pUNCH1426 Base pairs 73 to 438 deleted in dsrA (corresponding to amino acids 25 to 146) DsrAI25-146 This study
pUNCH1427 Base pairs 73 to 399 deleted in dsrA (corresponding to amino acids 25 to 133) DsrAI25-133 This study
pUNCH1428 Base pairs 73 to 363 deleted in dsrA (corresponding to amino acids 25 to 121) DsrAI25-121 This study
pUNCH1429 Base pairs 73 to 330 deleted in dsrA (corresponding to amino acids 25 to 110) DsrAI25-110 This study
pUNCH1430 Base pairs 73 to 291 deleted in dsrA (corresponding to amino acids 25 to 97) DsrAI25-97 This study
pUNCH1431 Base pairs 73 to 195 deleted in dsrA (corresponding to amino acids 25 to 65) DsrAI25-65 This study
a CAT, chloramphenicol acetyl transferase cassette.
b The nucleotide positions are the positions in the dsrA ORF of H. ducreyi strain 35000 (GenBank accession no. AF187001).
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FN and VN binding assay. The unlabelled FN assay described previously was
used to determine the phenotypes of the dsrA mutations with respect to FN and
VN binding (22). In the assay either purified native plasma FN (catalog no.
F2006; Sigma, Missouri) or normal human serum (NHS) (source of VN) was
used. The integrated density of the Western blot bands was quantified with NIH
Image software (version 1.62) (http://rsb.info.nih.gov/nih-image/). The binding of
DsrAI in FX517 to ECM proteins was defined as 100% binding (mean band
density, 100). FN and VN binding assays were each repeated four times. The
average percentage of binding of each truncated DsrA protein to FN and VN
relative to the binding of DsrAI in FX517 in four experiments was determined
and is presented below as the “mean band density” along with a representative
Western blot.
Bactericidal assay. The bactericidal assay was carried out as previously de-
scribed (13). In brief, bacteria (200 CFU) were incubated with 50% fresh or
heated NHS at 34.5°C in the presence of 5% CO2 for 45 min, plated onto CA
plates, and incubated for 48 h at 34.5°C in the presence of 5% CO2. The results
were expressed as the percentage of survival in fresh NHS compared to the
survival in heated NHS ([CFU in fresh NHS/CFU in heated NHS]  100).
IgM binding assay. One millicurie of 125I-Na (Perkin-Elmer, Massachusetts)
was preactived in Iodo-Gen tubes (Pierce, Illinois) and added to 200 g of
purified human IgM (catalog no. I-8260; Sigma-Aldrich, Missouri). The iodina-
tion reaction was allowed to proceed for 9 min on ice and then quenched by
adding 50 l of a 10-mg/ml solution of tyrosine. The iodinated product was
desalted on a Bio-Gel column (Bio-Rad, California). The cpm associated with
the iodinated IgM (125I-IgM) was determined using a gamma counter (1271
Riagamma LKB Wallac).
Bacteria (approximately 1  107 CFU) were incubated with 125I-IgM (1  106
cpm) for 45 min at 34.5°C in a MultiscreenHTS-HV plate (catalog no.
MSHVN4B10; Millipore, Massachusetts) (1). After the incubation, the wells
were washed five times with 200 l of phosphate-buffered saline and allowed to
dry, and the numbers of bacterium-associated cpm were determined using a
gamma counter.
Statistical analyses. Statistical analysis of the data from the bactericidal assays
and the IgM, FN, and VN binding assays was performed using the SigmaStat
program (version 3.0.1a; Systat Software, California). A one-way analysis of
variance, followed by a Bonferroni t test for multiple comparisons with a control
group (DsrAI), was used for parametric data, as in the FN and IgM binding
assays. A one-way analysis of variance on ranks was performed for the nonpara-
metric data obtained in the bactericidal and VN binding assays; Dunn’s test was
used for multiple comparisons with a control group.
RESULTS
Domain identification for DsrA. In 2000, Hoiczyk and col-
leagues assigned domains to YadA and many other Oca (Oligo-
FIG. 1. Sequence alignment of selected TAA proteins. The mature protein sequences were aligned using CLUSTALW (http://workbench.sdsc
.edu) with default settings. The signal sequences were determined using the SignalP 3.0 server (http://www.cbs.dtu.dk/services/SignalP/). Under-
lining indicates helix secondary structures, whereas bold type indicates beta strands (obtained using http://bioinf.cs.ucl.ac.uk/psipred/). Boxes
indicate residues that are fully conserved or that show conservation of strong or weak groups (determined by CLUSTALW). Domains of YadA1,
adapted from the study of Hoiczyk et al. (19), are indicated under the protein sequences by horizontal lines and arrows that show where the
domains begin and end. In-frame dsrA deletion mutants, referred to by the designations of the truncated DsrA proteins (Table 1), are indicated
by circles that show the first amino acid of the truncated protein. In-frame dsrA mutants were constructed using plasmid pUNCH1260, which
expresses full-length dsrA. In-frame mutations fused the first three amino acids of the mature sequence (QQP) to the amino acids indicated by the
designations of the truncated DsrA proteins (see Table 1 and Fig. 2 for more details). SR indicates the smallest truncated DsrA protein to confer
serum resistance to FX517; FNVN indicates the smallest truncated DsrA protein that confers FN and VN binding to FX517. The head, neck,
and stalk are parts of the passenger (effector) domain; the coiled-coil and membrane anchor encompass the translocator () domain.
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meric coiled-coil adhesin) proteins (19); however, this group
was not able to assign a passenger domain (including head,
neck, and stalk domains) to the H. ducreyi DsrA protein. In
order to roughly identify domains of DsrA to guide our strat-
egy for deletion mutagenesis, an alignment of the DsrA pro-
teins from members of both classes of H. ducreyi strains with
YadA proteins (422-residue YadA1 and 455-residue YadA2)
and UspA2 (5) was created using CLUSTALW (see Materials
and Methods for the sequences used) (Fig. 1). The alignment
revealed that all five proteins share many features in their
C-terminal translocator domains (coiled-coil and membrane
anchor), including conservation of many residues and struc-
tural features, such as four -strands and an -helix (Fig. 1).
Based on comparison to the domains assigned to YadA in the
alignment (Fig. 1), the translocator domain of DsrAI was as-
signed to residues 150 to 236 inclusive (coiled-coil region for
residues 150 to 182 and membrane anchor from amino acid
183 to amino acid 236), as shown by Hoiczyk et al. (19). The
passenger domain of DsrAI was assigned to amino acids 1 to
149, with residues 1 to 93 assigned to the head domain, amino
acids 94 to 111 assigned to the neck region, and residues 112 to
149 assigned to the stalk domain (Fig. 1). The head and stalk
domains of both DsrA proteins appear to be much shorter than
the corresponding domains of the other proteins in the align-
ment, which was expected for one of the smallest TAAs (20).
Compared to the DsrA proteins from H. ducreyi class II strains
(DsrAII), DsrAI from strain 35000HP is 27 residues shorter.
The extra residues in DsrAII are present in the stalk domain
(15 more residues), in the neck domain (6 more residues),
and in the head domain (6 more residues) (Fig. 1). However,
in all sequenced class I H. ducreyi strains, one, two, or three
copies of the “NTHNINK” sequence of the DsrA protein are
present in the coiled-coil domain, which extends the length of
this domain in these proteins (13).
The daTAA program is a web-based tool that annotates
domains of TAAs (33; http://toolkit.tuebingen.mpg.de/dataa).
Using this program, only the translocator region, common to
all TAAs, was identified in DsrA. According to this program,
the membrane anchor region was assigned to residues 148 to
236 of the mature DsrA protein, while amino acids 111 to 177
make up the coiled-coil region.
Construction and expression profiles of in-frame dsrA dele-
tions in H. ducreyi strain FX517. Truncated DsrA proteins
were expressed from a shuttle plasmid (39) in H. ducreyi se-
rum-sensitive strain FX517, an isogenic dsrA mutant of type
strain 35000HP (13). Each dsrA deletion was made in frame
and contained the dsrA signal sequence (Fig. 2A). To aid in the
processing of truncated DsrA proteins, the coding sequence
for the three amino acids (QQP) beyond the signal sequence in
full-length dsrA was present in all constructs (Fig. 2A). An
extra glycine (G) residue was also present after the “QQP”
sequence in most constructs because of insertion of an XmaI
(C/CCGGG) cloning site (Fig. 2A). Sequencing revealed that
this was the only difference in the sequence other than the
desired deletions compared to wild-type dsrA. Plasmids ex-
pressing dsrA mutations also contained the coding sequence
for the translocator domain of DsrA (coiled-coil and mem-
brane anchor regions) since this domain is needed for expres-
sion of YadA, the prototypical TAA, at the cell surface (29).
In-frame mutations of the sequence encoding the passenger
domain of dsrA were chosen based on three criteria. First,
small conserved domains highlighted in the CLUSTALW
alignment (Fig. 1) were removed, based on the rationale that
domains or residues conserved in TAAs might be responsible
for essential functions. Second, naturally occurring restriction
sites were taken advantage of for cloning purposes. Third,
mutations that were approximately evenly spaced were con-
structed in order to maximize localization of the functional
domains while a minimum number of dsrA deletion mutants
were constructed. A schematic diagram of truncated DsrA
proteins is shown in Fig. 2A. For convenience, truncated DsrA
proteins are referred to below by the amino acid residues
deleted from their passenger domains compared to the full-
length immature DsrAI protein (Table 1).
TABLE 2. Oligonucleotides used in this study
Primer Description Sequence (533)a
DsrA121s Reverse primer used with DsrA611s, DsrA3776F, and
DsrA3737F to create pUNCH1424, pUNCH1425, and
pUNCH1426, respectively
TTTCCCGGGCTGCTGAGCCATTGTTGTAAT
DsrA611s Forward primer used with DsrA121s to create pUNCH1424 ATGCCCGGGCAAAATACACATAATATCAATAAG
DsrA3776F Forward primer used with DsrA121s to create pUNCH1425 CTAGAACCCGGGACTTATTTAGATG
DsrA3737F Forward primer used with DsrA121s to create pUNCH1426 AAAAATCCCGGGAATATTGATACTATAAGTAA
ATAT
DsrAxE Reverse primer used with DsrAxG, DsrAxF, DsrAxD,
DsrAxC, and DsrAxB to create pUNCH1427,
pUNCH1428, pUNCH1429, pUNCH1430, and
pUNCH1431, respectively
TTGCCCGGGCATACGATAAGAATCATCTAAATA
DsrAxB Forward primer used with DsrAxE to create pUNCH1431 AAGCCCGGGGAATGGATTTCTAAACAG
DsrAxC Forward primer used with DsrAxE to create pUNCH1430 TCTCCCGGGCCTATACTGTTATATCCGATGTC
DsrAxD Forward primer used with DsrAxE to create pUNCH1429 CAACCCGGGTAATCGGCAGCAG
DsrAxF Forward primer used with DsrAxE to create pUNCH1428 CTGAAATTGCCCGGGTATAGTTATTTTAACGAT
TTAAGAC
DsrAxG Forward primer used with DsrAxE to create pUNCH1427 AGACACGATCCCGGGTTAAAAGTTTCTGAT
GCAC
T3 Sequencing primer ATTAACCCTCACTAAAGGGA
T7 Sequencing primer TAATACGACTCACTATAGGG
a Underlining indicates the XmaI site.
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Truncated DsrA proteins are present in the outer mem-
brane and expressed at the surface of H. ducreyi strain FX517.
To determine the localization of the truncated DsrA proteins
in H. ducreyi strain FX517, bacterial cells were fractionated,
and OMPs were examined by Western blotting with anti-rFL-
DsrAI (Fig. 2B). Each truncated DsrA protein was found in the
Sarkosyl-insoluble fraction (Fig. 3A, panel 1), suggesting that
truncations in the passenger domain of DsrA did not affect its
localization to the outer membrane.
To ensure that the truncated DsrA proteins not only were
present in the outer membrane but also were exposed at the
surface of the bacterial cell, we subjected the strains expressing
the truncated DsrA proteins to a whole-cell binding assay using
anti-rNt-DsrAI (Fig. 2B), which bound to the surface of H.
ducreyi. Anti-rNt-DsrAI bound to six of eight truncated DsrA
proteins in whole-cell binding and Western blot analyses (Fig.
3B, top and bottom panels, respectively). Anti-rNt-DsrAI was
unable to recognize the shortest construct, DsrAI25-170,
since this antibody was prepared for the passenger domain of
DsrAI, a sequence not present in DsrAI25-170 (Fig. 2A).
DsrAI25-158, the second smallest construct, was also not
recognized by anti-rNt-DsrAI, perhaps due to the lack of im-
munogenicity or antigenicity of common residues present in
the immunogen and antigen.
In summary, each truncated DsrA protein fractionated in
the Sarkosyl-insoluble fraction. Furthermore, the surface-bind-
ing antibody anti-rNt-rDsrAI bound all truncated DsrA pro-
teins except DsrAI25-170 and DsrAI25-158.
The truncated DsrA proteins form trimers in the outer
membrane of H. ducreyi strain FX517. Trimerization of the
FIG. 2. Schematic diagrams of the H. ducreyi full-length and truncated DsrA proteins. (A) Schematic diagrams of the full-length and truncated
DsrA proteins. The arrows indicate the positions of the amino acids at the N-terminal ends of the truncated proteins compared to the sequence
of the immature (arrows above the boxes) or mature (arrows below the boxes) DsrAI protein. The striped boxes represent the translocator domain,
which includes the coiled-coil (CC) and membrane anchor (MA) regions (see text for details). SS, signal sequence; AA, amino acids. (B) Schematic
diagrams of the recombinant proteins used for production of the antibodies used in this study.
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passenger domain in YadA is necessary for expression of the
protein function (10, 29). To determine if truncated DsrA
proteins formed trimers, OMPs of FX517 expressing the con-
structs were subjected to solubilization at 37°C, a temperature
that preserves the quaternary structure of DsrA, and Western
blotting using the anti-rFL-DsrAI antibody. Most truncated
DsrA proteins appeared to form multimers in strain FX517;
the only exception was DsrAI25-170 (Fig. 3A, panel 2).
DsrAI25-170 migrated predominantly at approximately 8
kDa after it was boiled (Fig. 3A, panel 1). Upon solubilization
at 37°C, the observed band migrated to about 14 kDa, and
trimers were apparently absent (Fig. 3A, panel 2).
DltA, MOMP, and LOS are expressed similarly in all in-
frame dsrA deletion mutants. In addition to DsrA, the lectin
DltA and MOMP have been shown to have relatively minor
roles in serum resistance in H. ducreyi (18, 21). To ensure that
the expression of these outer membrane components was not
altered upon expression of in-frame dsrA deletion mutants in
strain FX517, the expression profiles of DltA and MOMP were
examined using Western blotting. Each mutant strain ap-
peared to express both proteins at a level similar to that seen
in FX517 expressing full-length DsrAI (data not shown).
In some bacterial systems, lipopolysaccharides (LPS) lacking
an O-antigen, termed LOS, have been shown to be involved in
serum resistance (28). In H. ducreyi, evidence obtained previ-
ously strongly suggested that differences in LOS structure play
no role in serum resistance (13, 32). Nevertheless, to ensure
that our findings were not affected by a change in this outer
membrane component, crude LOS were prepared from strains
expressing in-frame dsrA deletions and examined by using so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis and
silver staining. There was no visible difference in the LOS
profiles between FX517 expressing the in-frame dsrA deletions
and FX517 expressing an empty vector or DsrAI (data not
shown). Taken together, these data suggest that there were no
detectable differences in the expression of the outer membrane
components DltA, MOMP, and LOS in the dsrA deletion mu-
tants.
The C-terminal region of the passenger domain of DsrA is
required for expression of a serum resistance phenotype. To
determine the residues of DsrA required for serum resistance,
we examined the survival in 50% NHS of the H. ducreyi dsrA
mutant strain FX517 expressing truncated DsrA proteins.
FX517 is killed in the presence of 50% NHS (1% survival),
whereas the parent strain, strain 35000HP, is not killed (100%
survival) (1, 13, 21, 38). For the purposes of this study, serum
resistance was defined as 50% survival in 50% NHS (Fig.
4A). Positive control strain FX517 complemented with a plas-
mid containing the full-length dsrA ORF (DsrAI) exhibited
increased serum resistance (median level of survival in 50%
NHS, 126%) (Fig. 4A) compared to the serum resistance of
parent strain 35000HP (96% survival in 50% NHS) (data not
shown), as previously observed (1, 13, 21). Strain FX517 con-
taining an empty vector (pLSSK) (39) was killed in 50% NHS
(vector control in Fig. 2A). Expression of the five largest de-
letion constructs, DsrAI25-133, DsrAI25-121, DsrAI25-
110, DsrAI25-97, and DsrAI25-65, restored serum resis-
tance to strain FX517 (Fig. 4A). Strain FX517 expressing the
FIG. 3. Cell surface expression and trimer formation of truncated DsrA proteins. (A) Sarkosyl-insoluble OMPs (approximately 1 g per lane)
were solubilized at 100°C (panel 1) and 37°C (panel 2) and subjected to Western blotting with anti-rFL-DsrAI. (B) (Top panel) Whole-cell binding
assay with anti-rNt-DsrAI, a rabbit polyclonal antibody that binds to the surface of H. ducreyi. (Bottom panel) Total cellular proteins from the
indicated strains were solubilized at 100°C and subjected to Western blotting with anti-rNt-DsrAI. RLU, relative light units.
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three smallest constructs, DsrAI25-170, DsrAI25-158, and
DsrAI25-146, was serum susceptible since each mutant exhib-
ited less than 50% survival in 50% NHS. In conclusion, a
128-residue truncated DsrA protein (DsrAI25-133) was the
shortest DsrA protein that restored serum resistance to serum-
sensitive strain FX517 (Fig. 4A).
The IgM binding by this panel of strains was also deter-
mined. FX517 expressing mutant protein DsrAI25-146,
DsrAI25-121, DsrAI25-110, DsrAI25-97, or DsrAI25-65
bound levels of IgM not significantly different from the level of
IgM bound by FX517 expressing DsrAI (Fig. 4A). All other
truncated DsrA proteins bound an amount of IgM statistically
different from the amount bound by DsrAI expressed in
FX517.
The C-terminal portion of the DsrA passenger domain is
also required for binding to ECM proteins. Previously, we
showed that DsrA is the major FN binding protein in H.
ducreyi, although there was residual FN binding by the dsrA
mutant strain, which was attributed to the expression of
MOMP (22). The ability of truncated DsrA proteins to restore
FN or VN binding to strain FX517 was examined. Expression
of DsrAI in FX517 restored binding to VN and FN to wild-type
levels (defined as 100%) (Fig. 4B). For the purposes of this
study, we defined ECM protein binding as 50% binding com-
pared to the ECM protein binding by DsrAI expressed in
FX517. For statistical analysis, the binding of truncated pro-
teins expressed in strain FX517 was compared to the expres-
sion of DsrAI in FX517. FX517 expressing DsrAI25-121,
DsrAI25-110, DsrAI25-97, or DsrAI25-65 bound FN and VN
at levels similar to the levels observed for FX517 expressing
full-length DsrAI (Fig. 4B). Inversely, expression of DsrAI25-
170, DsrAI25-158, DsrAI25-146, or DsrAI25-133 in FX517
did not restore binding to FN and VN by FX517 compared to
the binding with full-length DsrAI (Fig. 4B). In other words,
the binding capacity of these truncated DsrA proteins was not
significantly different from that of strain FX517 expressing an
empty vector. Thus, the smallest truncated DsrA protein
that restored binding to FN and VN by strain FX517 was
DsrAI25-121. The next smallest DsrA truncated protein,
DsrAI25-133, was not able to bind FN and VN, yet it restored
serum resistance to strain FX517.
Correlation between the amounts of IgM bound at the sur-
face of strain FX517 expressing the truncated DsrA proteins
and the sizes of the DsrA proteins or serum resistance. The
data in Fig. 4A suggest that there may be correlations between
IgM binding and serum resistance or between IgM binding and
the size of the DsrA protein. To determine if there were
significant correlations, we subjected the data shown in Fig. 4A
to linear regression analysis. The correlation coefficient (r2)
was 0.753 when the sizes of the DsrA proteins were compared
with the amounts of IgM bound at the surface of strain FX517
expressing truncated DsrA proteins (Fig. 5A). The data indi-
cate that the size of the DsrA protein is inversely correlated
with the amount of IgM bound at the surface of H. ducreyi,
which suggests that the larger the DsrA protein, the less IgM is
bound at the surface. This confirms our previous results (1)
and is consistent with the hypothesis that DsrA may shield
epitopes at the surface of H. ducreyi.
A similar inverse correlation between the amount of IgM
bound at the surface of FX517 expressing truncated DsrA
proteins and serum resistance was also found (r2  0.702),
although this correlation did not appear to be as strong as the
correlation between IgM binding and the size of DsrA (Fig.
5B). These data suggest that in addition to the length of DsrA,
other factors may be involved in serum resistance by H. ducreyi.
DISCUSSION
In this study, in-frame deletions of the passenger domain of
the H. ducreyi TAA DsrA were constructed and expressed in
the isogenic dsrA strain FX517. Surface localization and trimer
formation of the truncated DsrA proteins were confirmed be-
FIG. 4. Localization of the domains of DsrA required for serum
resistance and ECM protein binding. (A) Survival (gray bars) in 50%
NHS of H. ducreyi dsrA mutant FX517 expressing truncated DsrA
proteins. The arrow indicates the shortest construct that is serum
resistant (50% survival in 50% NHS). The open bars indicate the
results obtained with the IgM binding assay. An asterisk indicates a
value that is statistically different from the value for strain FX517
expressing full-length DsrA (DsrAI) (P 	 0.05). The data are pre-
sented using a box plot because statistical analysis determined that
some data were not equally distributed. Each box indicates the median
and 25th and 75th percentiles, while the error bars indicate the 10th
and 90th percentiles. The filled circles indicate data for outliers within
the 5th and 95th percentiles. (B) FN and VN binding by the dsrA
mutant strain FX517 expressing truncated DsrA proteins. Whole cells
of H. ducreyi were mixed with purified FN or NHS (as a source of VN).
After binding, cells were washed to remove unbound ligand. Cell
pellets were subjected to Western blotting with the indicated antibod-
ies to determine binding to VN and FN. Both FN and VN binding
assays were repeated four times with FX517 expressing each truncated
DsrA protein. The blots shown are representative Western blots from
one of these experiments. The numbers below the Western blots indi-
cate the mean band densities calculated from the results of four ex-
periments. Band density, measured using NIH Image, was adjusted
using the value for FX517 expressing full-length dsrA (DsrAI), defined
as 100% binding. An asterisk indicates that a value is statistically
different from the value for strain FX517 expressing full-length DsrA
(DsrAI) (P 	 0.05).
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fore their survival in 50% NHS and their ability to bind to the
ECM proteins FN and VN were determined. The smallest
construct that restored serum resistance but not FN and VN
binding to strain FX517 was 128 amino acids long. These data
suggest that only 41 amino acids of the DsrA passenger do-
main, in addition to the conserved C-terminal translocator
domain, are necessary to protect H. ducreyi from the bacteri-
cidal activity of NHS. A construct encompassing 140 residues
of the DsrA protein restored both VN and FN binding to the
dsrA mutant strain FX517 and also provided protection against
the bactericidal activity of NHS. Thus, it appears that the
translocator domain and 53 residues of the passenger domain
are needed for binding of ECM proteins to H. ducreyi.
Interpretation of the localization data for truncated DsrA
proteins expressed in H. ducreyi strain FX517. The following
three methods were used to determine the cellular localization
and structure of the truncated DsrA proteins expressed in
strain FX517: cellular fractionation, trimer formation, and
binding by a surface-binding polyclonal antibody. All truncated
DsrA proteins were present in the outer membrane of strain
FX517 since all eight in-frame deletion constructs fractionated
in the Sarkosyl-insoluble fraction (Fig. 3A, panel 1). All of the
constructs except DsrAI25-170 formed trimers, suggesting
that there was proper conformation of seven of the eight trun-
cated proteins in the outer membrane of FX517 (Fig. 3A,
panel 2). Six of the eight truncated DsrA proteins were bound
by a surface-binding antibody, confirming the surface exposure
of these constructs (Fig. 3B, top panel). Thus, all of the con-
structs except DsrAI25-170 localized to the outer membrane
and in the proper conformation.
DsrAI25-170 and DsrAI25-158 were the only two con-
structs not recognized at the surface of H. ducreyi by anti-rNt-
DsrAI. DsrAI25-170 was not recognized by anti-rNt-DsrAI
because it does not share any sequence with the immunogen
used to prepare anti-rNt-DsrAI. There are three reasons why
anti-rNt-DsrAI may not have recognized DsrAI25-158 at the
surface of the bacterial cell. First, the deletion mutant may not
have had epitopes exposed at the surface of the bacterial cell.
Second, the truncated protein may have had epitopes present
at the cell surface, but the epitopes may not have been immu-
nogenic. Third, the truncated protein may not have been in-
serted into the outer membrane or may have had an improper
conformation. DsrAI25-158 was present in the outer mem-
brane and formed proper trimers, suggesting that there was
proper localization and structure at the cell surface. These
data, therefore, suggest that the epitopes at the surface of
H. ducreyi of DsrAI25-158, which were not recognized rNt-
DsrAI, are either not accessible to the probe or not immuno-
genic. It is likely that a lack of immunogenicity explains the
inability of anti-rNt-DsrAI to recognize DsrAI25-158; anti-
rNt-DsrAI did not react to DsrAI25-158 in a Western blot
(Fig. 3B, bottom panel) even though the immunogen used to
obtain this antibody shares 12 amino acids with DsrAI25-158.
Taken together, the differences in the observed phenotypes of
all the constructs except DsrAI25-170 cannot be dismissed
solely on the basis of a lack of localization or exposure of the
truncated DsrA proteins.
Domains of YadA involved in serum resistance in Yersinia
enterocolitica. Structure-function studies of Y. enterocolitica
YadA, the prototypical TAA, revealed that the stalk, but not
the head and neck domains, plays a role in serum resistance in
Y. enterocolitica, although some sections of this domain also
appear to be dispensable for this phenotype (29). A recent
study performed by the same group showed that the C-termi-
nal translocator domain of YadA is also involved in serum
resistance (2). Biedzka-Sarek and colleagues confirmed these
results when they recently studied the complement resistance
of mutants with a short deletion in the neck and stalk of YadA.
These workers concluded that deletions in the central part and
a deletion in the C-terminal section of the stalk decreased
serum resistance (7). Similar to what has been reported for
YadA, it appears that the stalk domain of DsrA is required
for expression of full serum resistance in H. ducreyi since
DsrAI25-133 restored full serum resistance to H. ducreyi
strain FX517 (Fig. 1 and Fig. 4).
Pathogens bind host VN to inactivate the complement cas-
cade. VN is a glycoprotein found both in the ECM and in
plasma. In the ECM, VN is an adhesin and acts as a major cell
attachment factor in cells (26). In plasma, VN prevents forma-
tion of the membrane attack complex of complement in both
FIG. 5. Correlations between the amounts of IgM bound at the surface of FX517 expressing truncated DsrA proteins and the sizes of the DsrA
proteins (A) and between IgM binding and the serum resistance of strain FX517 expressing truncated DsrA proteins (B). Data from Fig. 4 were
used to determine the correlations using Sigma Plot. For IgM binding and serum resistance, “maximum” refers to the amount of IgM bound at
the surface of strain FX517 expressing DsrAI, which was defined as 100%.
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the soluble and cell-associated forms of the membrane attack
complex (26). VN binding is involved in serum resistance in
some strains of the mucosal pathogen Moraxella catarrhalis (6).
VN binding by the TAA UspA2 of M. catarrhalis was respon-
sible for serum resistance in three of four strains that were
tested. The fourth M. catarrhalis strain (FIN2344) bound VN
relatively weakly compared to the other three M. catarrhalis
strains tested, and VN was not involved in serum resistance in
this strain. Hsf, a classical autotransporter of H. influenzae type
b, is responsible for serum resistance and VN binding (15).
Two binding sites for VN were identified in Hsf. VN binding by
H. influenzae type b was shown to contribute to serum resis-
tance.
DsrA prevents naturally occurring bactericidal IgM binding
at the surface of the bacterial cell and subsequent complement
activation and bactericidal killing of H. ducreyi (1). Since com-
plement was never activated in strain 35000HP, which ex-
presses DsrAI, we were not able to determine a role for VN
bound by DsrA in serum resistance. In this study, FX517 ex-
pressing DsrAI25-133 bound high levels of IgM but did not
bind VN (or FN) and remained serum resistant. We concluded
that VN (and FN) binding is not required for high-level serum
resistance in H. ducreyi.
Shielding as a hypothetical mechanism of serum resistance
by the H. ducreyi DsrA protein. Shielding of immunogenic
components at the surface of the cell by other factors is an old
concept (37). The capsule and the O-antigen of LPS have been
shown to have roles in shielding surface epitopes from the
humoral components and are involved in resistance to the
bactericidal activity of serum (14, 27, 28, 30). H. ducreyi does
not express a capsule, and the LPS molecule does not have an
O-antigen. Instead, H. ducreyi strain 35000HP expresses LOS,
which is not involved in serum resistance even though it is
highly sialylated, a feature of neisserial LOS involved in serum
resistance (13, 18, 25). H. ducreyi is highly resistant to the
bactericidal activity of NHS, mainly due to the presence of the
major outer membrane TAA DsrA (13). Based on previous
work, we hypothesized that DsrA may shield epitopes at the
surface of the bacteria. This hypothesis is supported by the
inverse correlation between the size of the DsrA protein and
the amount of IgM bound at the surface of the cell (r2  0.753)
described in this report (Fig. 5A).
Other bacterial and host components may be involved in
serum resistance in H. ducreyi. In this study, we demonstrated
that there is a correlation (r2  0.702) between the amount of
serum IgM bound at the surface of the dsrA mutants and the
level of serum resistance of these mutants (Fig. 5B). However,
IgM binding is not absolutely correlated with killing in all
strains. Furthermore, the DsrAI25-133 mutant appeared to
be serum resistant in the presence of 50% NHS, although the
amount of IgM bound at its surface was significantly larger
than the amount present on FX517 expressing DsrAI. These
data suggest that there may be (an)other factor(s) that pre-
vents complement from killing H. ducreyi in addition to anti-
body binding to the surface of the cell.
In summary, we identified two separate domains of the H.
ducreyi TAA DsrA required for serum resistance and ECM
protein binding. In doing this, we established that neither FN
binding nor VN binding is involved in the expression of a
serum resistance phenotype in H. ducreyi.
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